Atika Capital Management LLC Has $25.58 Million Position in Inspire Medical Systems, Inc. $INSP

Key Points

• Atika Capital Management LLC increased its stake in Inspire Medical Systems by 1.9%, now holding 160,600 shares worth approximately $25.58 million.
• Analysts have varying outlooks on Inspire Medical Systems, with price targets ranging from a low of $97.00 to a high of $236.00 reflecting differing views on the company's performance.
• Inspire Medical Systems recently announced a $200 million stock repurchase program, indicating confidence in its valuation by the company's leadership.

Atika Capital Management LLC boosted its position in shares of Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 1.9% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 160,600 shares of the company's stock after buying an additional 3,000 shares during the period. Inspire Medical Systems makes up approximately 3.6% of Atika Capital Management LLC's investment portfolio, making the stock its 10th largest position. Atika Capital Management LLC owned about 0.54% of Inspire Medical Systems worth $25,580,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. True Wealth Design LLC grew its stake in Inspire Medical Systems by 39.0% during the fourth quarter. True Wealth Design LLC now owns 196 shares of the company's stock worth $36,000 after buying an additional 55 shares in the last quarter. Parallel Advisors LLC grew its stake in Inspire Medical Systems by 356.5% during the first quarter. Parallel Advisors LLC now owns 210 shares of the company's stock worth $33,000 after buying an additional 164 shares in the last quarter. GAMMA Investing LLC grew its stake in Inspire Medical Systems by 253.7% during the first quarter. GAMMA Investing LLC now owns 573 shares of the company's stock worth $91,000 after buying an additional 411 shares in the last quarter. Archer Investment Corp acquired a new stake in Inspire Medical Systems during the first quarter worth about $96,000. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Inspire Medical Systems during the fourth quarter worth about $166,000. 94.91% of the stock is currently owned by institutional investors and hedge funds.

Inspire Medical Systems Trading Up 4.6%

NYSE:INSP traded up $4.1780 during mid-day trading on Friday, hitting $95.7980. 559,798 shares of the company's stock were exchanged, compared to its average volume of 1,655,434. The company has a 50 day simple moving average of $117.55 and a 200-day simple moving average of $144.47. Inspire Medical Systems, Inc. has a fifty-two week low of $73.92 and a fifty-two week high of $225.00. The firm has a market capitalization of $2.83 billion, a P/E ratio of 55.37, a PEG ratio of 2.99 and a beta of 1.22.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.22 by $0.23. Inspire Medical Systems had a net margin of 6.17% and a return on equity of 10.38%. The business had revenue of $217.09 million for the quarter, compared to the consensus estimate of $214.50 million. During the same period last year, the company earned $0.32 EPS. The firm's revenue was up 10.8% compared to the same quarter last year. Inspire Medical Systems has set its FY 2025 guidance at 0.400-0.500 EPS. As a group, analysts expect that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current year.

Inspire Medical Systems announced that its board has approved a stock repurchase program on Monday, August 11th that allows the company to buyback $200.00 million in outstanding shares. This buyback authorization allows the company to purchase up to 8.6% of its stock through open market purchases. Stock buyback programs are often an indication that the company's board of directors believes its shares are undervalued.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on INSP shares. Lake Street Capital set a $150.00 price objective on shares of Inspire Medical Systems and gave the stock a "buy" rating in a research note on Tuesday, August 5th. Stifel Nicolaus set a $140.00 price target on shares of Inspire Medical Systems and gave the company a "hold" rating in a research note on Tuesday, August 5th. Truist Financial restated a "hold" rating and issued a $125.00 price target (down from $190.00) on shares of Inspire Medical Systems in a research note on Tuesday, August 5th. Robert W. Baird raised their price target on shares of Inspire Medical Systems from $230.00 to $236.00 and gave the company an "outperform" rating in a research note on Tuesday, May 6th. Finally, Royal Bank Of Canada reduced their price target on shares of Inspire Medical Systems from $215.00 to $180.00 and set an "outperform" rating on the stock in a research note on Tuesday, August 5th. Seven equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat, Inspire Medical Systems presently has a consensus rating of "Moderate Buy" and an average price target of $165.62.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.